Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ: CDXC) announces that its patented nicotinamide riboside (NR) ingredient, Niagen®, has been selected as the key ingredient in Longevity.Technology's new supplement. Niagen, recognized as the gold standard for NAD+ supplementation, is backed by over 30 peer-reviewed human clinical studies showing benefits in cellular, brain, heart, and muscle health. The company's intellectual property portfolio includes 90+ owned and licensed patents. Niagen is available through business partnerships and is the active ingredient in ChromaDex's Tru Niagen brand, currently the leading healthy-aging NAD+ supplement in the United States.
ChromaDex Corp. (NASDAQ:CDXC) has announced the nationwide rollout of its Niagen® IV products at over 200 Restore Hyper Wellness locations across the United States. Niagen IV, a pharmaceutical-grade nicotinamide riboside chloride (NRC) product, represents an advancement in NAD+ therapy, offering superior benefits compared to traditional NAD+ IV treatments. In clinical studies, Niagen IV demonstrated a 75% shorter infusion time, better tolerability, and achieved a 20% increase in whole blood NAD+ levels three hours post-infusion. The product is compounded and distributed by Wells Pharma of Houston, an FDA-registered 503B facility, and is available exclusively for clinics with medical clearance.
ChromaDex (NASDAQ:CDXC) reported strong Q3 2024 financial results with total net sales of $25.6 million, up 31% year-over-year. The company achieved record net income of $1.9 million ($0.02 per share) and Adjusted EBITDA of $2.9 million. Tru Niagen® sales reached $18.1 million, while Niagen® ingredient sales surged 368% to $6.7 million. Gross margin improved to 63.5%. The company expanded its Niagen+ product line to over 100 wellness clinics and expects approximately 15% revenue growth for full-year 2024.
ChromaDex Corp. (NASDAQ: CDXC) has rescheduled its third quarter 2024 financial results conference call to Thursday, October 31, 2024, at 4:30 p.m. ET. The company, which specializes in NAD+ research and healthy aging, will release its financial results for the quarter ended September 30, 2024, after market close on the same day. The conference call will include management discussion and a general business update. A replay of the call will be available until November 13, 2024.
ChromaDex Corp. (NASDAQ:CDXC) has announced it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after market close. The company will host an investor conference call to discuss the results and provide a business update on Wednesday, November 6, 2024, at 4:30 p.m. ET. Management encourages participants to join 10 minutes before the call. A replay will be available from 7:30 p.m. EDT on November 6 until 11:59 p.m. EDT on November 13, 2024.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its participation in the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. CEO Rob Fried and CFO Ozan Pamir will deliver a presentation at 2:00pm PT (5:00pm ET). The event will showcase 150 companies and include private one-on-one meetings with institutional investors. ChromaDex management will be available for individual meetings throughout the day. Interested parties can watch the live presentation through a provided webcast link and access additional company information through the LD Micro profile page.
ChromaDex Corp. (NASDAQ:CDXC) announced that Dr. Yasmeen Nkrumah-Elie, their Global Director of External Research, has been honored with the inaugural Trailblazing Woman Award by Radicle Science and the Council for Responsible Nutrition (CRN). This award recognizes Dr. Nkrumah-Elie's contributions to the dietary supplement and functional food industry through leadership, innovation, and mentorship.
Dr. Nkrumah-Elie has led ChromaDex's External Research Program (CERP) to become an industry-leading initiative with nearly 300 research collaborations worldwide, over 30 published clinical trials, and several intellectual property opportunities. She is also active in various industry organizations, advocating for diversity, equity, and inclusion.
The award highlights Dr. Nkrumah-Elie's commitment to advancing scientific excellence, promoting diversity, and mentoring the next generation of female leaders in the industry.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ and healthy-aging research, has announced its participation in the Lytham Partners Fall 2024 Investor Conference. CEO Rob Fried will engage in a fireside chat on October 1, 2024, at 1:15 PM ET, moderated by Sean McGowan from Roth Capital Partners. The webcast will be accessible via a provided link and the company's website.
Additionally, Fried and Wesley Yu, VP of Finance, will host virtual one-on-one meetings with investors. Interested parties can arrange meetings through Lytham Partners or register for the event online. This participation underscores ChromaDex's commitment to investor relations and showcases its position in the healthy-aging research sector.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Ozan Pamir as Chief Financial Officer, effective October 21, 2024. Mr. Pamir will oversee all corporate finance matters, including accounting, strategic financial planning, and investor relations, reporting directly to CEO Rob Fried. Prior to joining ChromaDex, Pamir served as CFO of 180 Life Sciences, where he played a key role in the company's NASDAQ listing and managed funding rounds. He has also worked with two early-stage biotech companies as CFO and board member, and was previously VP of Investment Banking at a leading independent investment bank. Mr. Pamir holds an Economics and Finance degree from McGill University and is a CFA Charterholder.
ChromaDex Corp. (NASDAQ:CDXC) has announced the expansion of its pharmaceutical-grade Niagen® (nicotinamide riboside chloride) IV and injection offerings to 14 additional leading wellness clinics across the United States. This follows the successful debut of quantities in select clinics last month. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute the product, branded as Niagen+, exclusively to these clinics with a prescription.
Niagen, ChromaDex's flagship ingredient, is clinically proven to elevate NAD+ levels, important for cellular health. The IV and injection formulations offer rapid and efficient delivery, outperforming NAD+ IV in a pilot clinical study with superior tolerability, 75% shorter infusion time, and a significant 20% increase in whole blood NAD+ levels. Several clinic directors have expressed excitement about the potential of Niagen IV in health optimization and longevity treatments.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
